The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TRVI | +214.57% | +377.15% | +36.69% | +61% |
| S&P | +15.98% | +86.41% | +13.26% | +139% |
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
No news articles found for Trevi Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$38.00K | -5.6% |
| Market Cap | $1.11B | 359.6% |
| Market Cap / Employee | $42.86M | 0.0% |
| Employees | 26 | 4.0% |
| Net Income | -$11,802.00K | 10.9% |
| EBITDA | -$13,878.00K | 1.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $56.87M | 254.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $527.00K | -35.4% |
| Short Term Debt | $296.00K | -0.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -34.19% | 19.6% |
| Return On Invested Capital | -63.94% | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9,557.00K | -49.8% |
| Operating Free Cash Flow | -$10,880.00K | -13.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.27 | 5.91 | 5.49 | 5.61 | 53.21% |
| Price to Tangible Book Value | 5.27 | 5.91 | 5.49 | 5.61 | 53.21% |
| Enterprise Value to EBITDA | -27.05 | -55.76 | -37.27 | -81.68 | 319.03% |
| Return on Equity | -52.6% | -55.1% | -35.7% | -36.9% | -38.19% |
| Total Debt | $1.03M | $957.00K | $891.00K | $823.00K | -26.06% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
